Trial · NCT02606305
Adverse events7,557
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 7,557
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | 1 | 3 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | 85 | 126 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | 4 | 4 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | 3 | 4 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | 5 | 10 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | 3 | 4 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | 4 | 5 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | 4 | 7 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | 2 | 4 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine 6 mg/kg + Pembrolizumab 200 mg | 32 | 56 | |
| other | Diarrhoea | Gastrointestinal disorders | Mirvetuximab Soravtansine + Bevacizumab + Carboplatin | 34 | 41 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Bevacizumab 15 mg/kg | 2 | 3 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 6 mg/kg + Bevacizumab 15 mg/kg | 73 | 126 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC4 | 1 | 4 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Carboplatin AUC5 | 2 | 4 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 6 mg/kg + Carboplatin AUC5 | 10 | 10 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + PLD 30 mg/m^2 | 1 | 4 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + PLD 40 mg/m^2 | 4 | 5 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 6 mg/kg + PLD 40 mg/m^2 | 6 | 7 | |
| other | Nausea | Gastrointestinal disorders | Mirvetuximab Soravtansine 5 mg/kg + Pembrolizumab 200 mg | 3 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02606305/events